> top > docs > PubMed:14743461 > annotations

PubMed:14743461 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-63 Sentence denotes Characteristics of prostate cancers detected at low PSA levels.
TextSentencer_T2 64-75 Sentence denotes BACKGROUND:
TextSentencer_T3 76-274 Sentence denotes When age-referenced PSA levels as recommended by Oesterling et al.1 were used as a biopsy criterion, only 25% of the cancers detected in a population based PSA Screening Project were organ-confined.
TextSentencer_T4 275-368 Sentence denotes This observation led to the decision to use low PSA levels as the sole indication for biopsy.
TextSentencer_T5 369-496 Sentence denotes Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%.
TextSentencer_T6 497-663 Sentence denotes This PSA cutoff reduction led to a statistically significant migration to lower pathological stages with a decreased prostate cancer mortality in the years 1996-2001.
TextSentencer_T7 664-778 Sentence denotes However, concerns have been raised that screening with low PSA levels may detect clinically insignificant cancers.
TextSentencer_T8 779-801 Sentence denotes MATERIALS AND METHODS:
TextSentencer_T9 802-984 Sentence denotes We evaluated prostate cancer patients with low PSA levels in terms of heterogeneity, clinical significance, multifocality, and tumor biology including ploidy and proliferation index.
TextSentencer_T10 985-993 Sentence denotes RESULTS:
TextSentencer_T11 994-1408 Sentence denotes Concerning heterogeneity the Gleason score of the needle biopsy failed to predict the Gleason score of the radical prostatectomy specimen in nearly 40% of prostate cancer patients; regarding multifocality 65% of patients with low PSA levels showed multifocal lesions and 36% exhibited tetraploid DNA distribution; more than 50% of tetraploid tumors were found in patients with tumor volumes of less than 0.5 cm(3).
TextSentencer_T12 1409-1489 Sentence denotes Ploidy correlated with the Ki-67 proliferation index, but not with tumor volume.
TextSentencer_T13 1490-1502 Sentence denotes CONCLUSIONS:
TextSentencer_T14 1503-1783 Sentence denotes These results demonstrate that small prostate cancers with low PSA levels and low tumor volumes exhibit all features of prostate cancers with higher tumor volumes and show the characteristics of malignant cancers, i.e., multifocality, tetraploidy, and high proliferative activity.
T1 0-63 Sentence denotes Characteristics of prostate cancers detected at low PSA levels.
T2 64-75 Sentence denotes BACKGROUND:
T3 76-274 Sentence denotes When age-referenced PSA levels as recommended by Oesterling et al.1 were used as a biopsy criterion, only 25% of the cancers detected in a population based PSA Screening Project were organ-confined.
T4 275-368 Sentence denotes This observation led to the decision to use low PSA levels as the sole indication for biopsy.
T5 369-496 Sentence denotes Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%.
T6 497-663 Sentence denotes This PSA cutoff reduction led to a statistically significant migration to lower pathological stages with a decreased prostate cancer mortality in the years 1996-2001.
T7 664-778 Sentence denotes However, concerns have been raised that screening with low PSA levels may detect clinically insignificant cancers.
T8 779-801 Sentence denotes MATERIALS AND METHODS:
T9 802-984 Sentence denotes We evaluated prostate cancer patients with low PSA levels in terms of heterogeneity, clinical significance, multifocality, and tumor biology including ploidy and proliferation index.
T10 985-993 Sentence denotes RESULTS:
T11 994-1408 Sentence denotes Concerning heterogeneity the Gleason score of the needle biopsy failed to predict the Gleason score of the radical prostatectomy specimen in nearly 40% of prostate cancer patients; regarding multifocality 65% of patients with low PSA levels showed multifocal lesions and 36% exhibited tetraploid DNA distribution; more than 50% of tetraploid tumors were found in patients with tumor volumes of less than 0.5 cm(3).
T12 1409-1489 Sentence denotes Ploidy correlated with the Ki-67 proliferation index, but not with tumor volume.
T13 1490-1502 Sentence denotes CONCLUSIONS:
T14 1503-1783 Sentence denotes These results demonstrate that small prostate cancers with low PSA levels and low tumor volumes exhibit all features of prostate cancers with higher tumor volumes and show the characteristics of malignant cancers, i.e., multifocality, tetraploidy, and high proliferative activity.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 193-200 HP_0002664 denotes cancers
T2 614-629 HP_0012125 denotes prostate cancer
T3 623-629 HP_0002664 denotes cancer
T4 770-777 HP_0002664 denotes cancers

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
14743461-0#52#55#gene354 723-726 gene354 denotes PSA
14743461-0#52#55#gene9520 723-726 gene9520 denotes PSA
14743461-0#52#55#gene5324 723-726 gene5324 denotes PSA
14743461-0#52#55#gene5627 723-726 gene5627 denotes PSA
14743461-0#52#55#gene29968 723-726 gene29968 denotes PSA
14743461-0#19#35#diseaseC0376358 364-591 diseaseC0376358 denotes psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
14743461-7#230#233#gene354 1224-1227 gene354 denotes PSA
14743461-7#230#233#gene9520 1224-1227 gene9520 denotes PSA
14743461-7#230#233#gene5324 1224-1227 gene5324 denotes PSA
14743461-7#230#233#gene5627 1224-1227 gene5627 denotes PSA
14743461-7#230#233#gene29968 1224-1227 gene29968 denotes PSA
14743461-7#155#170#diseaseC0600139 1149-1164 diseaseC0600139 denotes prostate cancer
52#55#gene35419#35#diseaseC0376358 14743461-0#52#55#gene354 14743461-0#19#35#diseaseC0376358 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
52#55#gene952019#35#diseaseC0376358 14743461-0#52#55#gene9520 14743461-0#19#35#diseaseC0376358 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
52#55#gene532419#35#diseaseC0376358 14743461-0#52#55#gene5324 14743461-0#19#35#diseaseC0376358 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
52#55#gene562719#35#diseaseC0376358 14743461-0#52#55#gene5627 14743461-0#19#35#diseaseC0376358 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
52#55#gene2996819#35#diseaseC0376358 14743461-0#52#55#gene29968 14743461-0#19#35#diseaseC0376358 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
230#233#gene354155#170#diseaseC0600139 14743461-7#230#233#gene354 14743461-7#155#170#diseaseC0600139 associated_with PSA,prostate cancer
230#233#gene9520155#170#diseaseC0600139 14743461-7#230#233#gene9520 14743461-7#155#170#diseaseC0600139 associated_with PSA,prostate cancer
230#233#gene5324155#170#diseaseC0600139 14743461-7#230#233#gene5324 14743461-7#155#170#diseaseC0600139 associated_with PSA,prostate cancer
230#233#gene5627155#170#diseaseC0600139 14743461-7#230#233#gene5627 14743461-7#155#170#diseaseC0600139 associated_with PSA,prostate cancer
230#233#gene29968155#170#diseaseC0600139 14743461-7#230#233#gene29968 14743461-7#155#170#diseaseC0600139 associated_with PSA,prostate cancer

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 259-264 http://purl.obolibrary.org/obo/UBERON_0000062 denotes organ

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T578 723-726 gene:354 denotes PSA
T579 364-591 disease:C0376358 denotes psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
R1 T578 T579 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
R2 T578 T579 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
R3 T578 T579 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
R4 T578 T579 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s
R5 T578 T579 associated_with PSA,psy. Since 1995 age-referenced PSA levels of 1.25-3.25 ng/ml have been used in combination with a percentage free PSA cutoff of 18%. This PSA cutoff reduction led to a statistically significant migration to lower pathological s

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 259-264 http://purl.obolibrary.org/obo/UBERON_0000062 denotes organ

DisGeNET

Id Subject Object Predicate Lexical cue
T0 1566-1569 gene:5627 denotes PSA
T1 1540-1556 disease:C0376358 denotes prostate cancers
T2 1566-1569 gene:5324 denotes PSA
T3 1540-1556 disease:C0376358 denotes prostate cancers
T4 1566-1569 gene:354 denotes PSA
T5 1540-1556 disease:C0376358 denotes prostate cancers
T6 1566-1569 gene:9520 denotes PSA
T7 1540-1556 disease:C0376358 denotes prostate cancers
T8 1566-1569 gene:29968 denotes PSA
T9 1540-1556 disease:C0376358 denotes prostate cancers
T10 1566-1569 gene:5627 denotes PSA
T11 1623-1639 disease:C0376358 denotes prostate cancers
T12 1566-1569 gene:5324 denotes PSA
T13 1623-1639 disease:C0376358 denotes prostate cancers
T14 1566-1569 gene:354 denotes PSA
T15 1623-1639 disease:C0376358 denotes prostate cancers
T16 1566-1569 gene:9520 denotes PSA
T17 1623-1639 disease:C0376358 denotes prostate cancers
T18 1566-1569 gene:29968 denotes PSA
T19 1623-1639 disease:C0376358 denotes prostate cancers
T20 1566-1569 gene:5627 denotes PSA
T21 1708-1715 disease:C0006826 denotes cancers
T22 1566-1569 gene:5324 denotes PSA
T23 1708-1715 disease:C0006826 denotes cancers
T24 1566-1569 gene:354 denotes PSA
T25 1708-1715 disease:C0006826 denotes cancers
T26 1566-1569 gene:9520 denotes PSA
T27 1708-1715 disease:C0006826 denotes cancers
T28 1566-1569 gene:29968 denotes PSA
T29 1708-1715 disease:C0006826 denotes cancers
R1 T0 T1 associated_with PSA,prostate cancers
R2 T2 T3 associated_with PSA,prostate cancers
R3 T4 T5 associated_with PSA,prostate cancers
R4 T6 T7 associated_with PSA,prostate cancers
R5 T8 T9 associated_with PSA,prostate cancers
R6 T10 T11 associated_with PSA,prostate cancers
R7 T12 T13 associated_with PSA,prostate cancers
R8 T14 T15 associated_with PSA,prostate cancers
R9 T16 T17 associated_with PSA,prostate cancers
R10 T18 T19 associated_with PSA,prostate cancers
R11 T20 T21 associated_with PSA,cancers
R12 T22 T23 associated_with PSA,cancers
R13 T24 T25 associated_with PSA,cancers
R14 T26 T27 associated_with PSA,cancers
R15 T28 T29 associated_with PSA,cancers